These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 10931809)

  • 1. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production.
    Broeders MA; Doevendans PA; Bekkers BC; Bronsaer R; van Gorsel E; Heemskerk JW; Egbrink MG; van Breda E; Reneman RS; van Der Zee R
    Circulation; 2000 Aug; 102(6):677-84. PubMed ID: 10931809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms.
    Ignarro LJ; Byrns RE; Trinh K; Sisodia M; Buga GM
    Nitric Oxide; 2002 Sep; 7(2):75-82. PubMed ID: 12223176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of nitric oxide release by nebivolol and its metabolites.
    Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
    Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.
    Evangelista S; Garbin U; Pasini AF; Stranieri C; Boccioletti V; Cominacini L
    Pharmacol Res; 2007 Apr; 55(4):303-9. PubMed ID: 17280840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation.
    Maffei A; Di Pardo A; Carangi R; Carullo P; Poulet R; Gentile MT; Vecchione C; Lembo G
    Hypertension; 2007 Oct; 50(4):652-6. PubMed ID: 17664392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
    Ignarro LJ
    Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
    Cosentino F; Bonetti S; Rehorik R; Eto M; Werner-Felmayer G; Volpe M; Lüscher TF
    J Hypertens; 2002 Mar; 20(3):421-8. PubMed ID: 11875309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.
    Rozec B; Quang TT; Noireaud J; Gauthier C
    Br J Pharmacol; 2006 Apr; 147(7):699-706. PubMed ID: 16474420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor-mediated vascular responsiveness to nebivolol: a novel endothelium-related mechanism of therapeutic vasorelaxation.
    Garbán HJ; Buga GM; Ignarro LJ
    J Cardiovasc Pharmacol; 2004 May; 43(5):638-44. PubMed ID: 15071350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
    Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
    Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells.
    Brehm BR; Wolf SC; Bertsch D; Klaussner M; Wesselborg S; Schüler S; Schulze-Osthoff K
    Cardiovasc Res; 2001 Feb; 49(2):430-9. PubMed ID: 11164853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney.
    Kakoki M; Hirata Y; Hayakawa H; Nishimatsu H; Suzuki Y; Nagata D; Suzuki E; Kikuchi K; Nagano T; Omata M
    Hypertension; 1999 Jan; 33(1 Pt 2):467-71. PubMed ID: 9931149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebivolol induces calcium-independent signaling in endothelial cells by a possible beta-adrenergic pathway.
    Gosgnach W; Boixel C; Névo N; Poiraud T; Michel JB
    J Cardiovasc Pharmacol; 2001 Aug; 38(2):191-9. PubMed ID: 11483868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol: endothelium-mediated vasodilating effect.
    Ritter JM
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.
    Oelze M; Daiber A; Brandes RP; Hortmann M; Wenzel P; Hink U; Schulz E; Mollnau H; von Sandersleben A; Kleschyov AL; Mülsch A; Li H; Förstermann U; Münzel T
    Hypertension; 2006 Oct; 48(4):677-84. PubMed ID: 16940222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol-induced vasodilation of renal afferent arterioles involves β3-adrenergic receptor and nitric oxide synthase activation.
    Feng MG; Prieto MC; Navar LG
    Am J Physiol Renal Physiol; 2012 Sep; 303(5):F775-82. PubMed ID: 22674024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
    Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
    Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.